Literature DB >> 11276107

A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution.

L O Johansson1, A Bjørnerud, H K Ahlström, D L Ladd, D K Fujii.   

Abstract

A preparation of ultra-small superparamagnetic iron oxide (USPIO) particles coupled to an RGD peptide (RGD-USPIO) was investigated as an MR contrast agent, targeted to activated platelets, in both ex vivo and in vivo thrombus models. Thrombus visualization ex vivo was compared using RGD-USPIO and a non-targeted UPSIO. The influence of thrombus visualization on thrombus exposure time to RGD-USPIO (ex vivo) and on the spatial resolution of the MR image (ex vivo and in vivo) was assessed. RGD-USPIO resulted in better thrombus visualization than non-targeted USPIO ex vivo, and maximum enhancement was achieved after approximately one hour exposure time of the thrombus to RGD-USPIO. The ability to visualize the clots was highly dependent on the spatial resolution of the image. In vivo, an in-plane resolution of less than 0.2 x 0.2 mm(2) was required for good clot visualization after contrast enhancement. It is concluded that the achievable resolution and sensitivity is a potential limitation to the usefulness of active vascular targeting in MRI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11276107     DOI: 10.1002/jmri.1086

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  23 in total

Review 1.  Targeted probes for cardiovascular MRI.

Authors:  Ritika Uppal; Peter Caravan
Journal:  Future Med Chem       Date:  2010-03       Impact factor: 3.808

Review 2.  Magnetic resonance imaging of coronary atherosclerosis.

Authors:  Zahi A Fayad; Robin P Choudhury; Valentin Fuster
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 3.  Magnetic resonance molecular imaging with nanoparticles.

Authors:  Gregory M Lanza; Patrick M Winter; Shelton D Caruthers; Anne M Morawski; Anne H Schmieder; Katherine C Crowder; Samuel A Wickline
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

Review 4.  Cardiovascular magnetic resonance imaging of coronary atherothrombosis.

Authors:  W Yong Kim; Elmar Spuentrup; Arno Buecker; Warren J Manning; René M Botnar
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

5.  Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation.

Authors:  M M Stollenwerk; I Pashkunova-Martic; C Kremser; H Talasz; G C Thurner; A A Abdelmoez; E A Wallnöfer; A Helbok; E Neuhauser; N Klammsteiner; L Klimaschewski; E von Guggenberg; E Fröhlich; B Keppler; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2010-02-20       Impact factor: 4.304

Review 6.  Coronary magnetic resonance imaging: visualization of the vessel lumen and the vessel wall and molecular imaging of arteriothrombosis.

Authors:  Elmar Spuentrup; Rene M Botnar
Journal:  Eur Radiol       Date:  2005-08-25       Impact factor: 5.315

7.  Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.

Authors:  Ian R Corbin; Hui Li; Juan Chen; Sissel Lund-Katz; Rong Zhou; Jerry D Glickson; Gang Zheng
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

8.  Conquering the dark side: colloidal iron oxide nanoparticles.

Authors:  Angana Senpan; Shelton D Caruthers; Ilsu Rhee; Nicholas A Mauro; Dipanjan Pan; Grace Hu; Michael J Scott; Ralph W Fuhrhop; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal:  ACS Nano       Date:  2009-12-22       Impact factor: 15.881

Review 9.  Recent developments and new perspectives on imaging of atherosclerotic plaque: role of anatomical, cellular and molecular MRI part III.

Authors:  Bernard C M te Boekhorst; Maarten-Jan M Cramer; Gerard Pasterkamp; Cees J A van Echteld; Pieter A F M Doevendans
Journal:  Int J Cardiovasc Imaging       Date:  2010-01-08       Impact factor: 2.357

10.  Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths.

Authors:  Constantin von Zur Muhlen; Dominik von Elverfeldt; Robin Paul Choudhury; Janine Ender; Ingo Ahrens; Meike Schwarz; Jürgen Hennig; Christoph Bode; Karlheinz Peter
Journal:  Mol Imaging       Date:  2008 Mar-Apr       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.